The Indian multinational pharmaceutical company based in Mumbai Lupin today announced that it will enter the digital healthcare space in India with a focus to provide a digital therapeutics platform for doctors and patients.

In a regulatory filing, the company said, "the board of directors has approved the company's entry into the digital healthcare space."

The company stated that it has recently incorporated a new entity in the name of Lupin Digital Health Ltd, as a wholly-owned subsidiary, which will undertake this, the filing added.

Lupin, however, did not share any other details about the new venture. Lupin's businesses encompass the entire pharmaceutical value chain, ranging from branded and generic formulations, APIs, advanced drug delivery systems to biotechnology.

Lupin Limited is an Indian multinational pharmaceutical company based in Mumbai, Maharashtra, India. It is one of the largest generic pharmaceutical companies by revenue globally. The company's key focus areas include paediatrics, cardiovascular, anti-infectives, diabetology, asthma and anti-tuberculosis. Shares of Lupin Ltd were trading 0.29 per cent lower at Rs.1,243.30 apiece on BSE.

Lupin's IRF business focuses on Lifestyle diseases and Chronic disease therapy segments, particularly in Cardiology, Central Nervous System (CNS), Diabetology, Anti-Asthma, Anti-Infective, Gastro Intestinal and Oncology.

It has 12 manufacturing plants and 2 Research plants in India, as Jammu(J&K), Mandideep & Indore (Madhya pradesh), Ankaleswar & Dabasa (Gujarat), Tarapur, Aurangabad and Nagpur (Maharashtra), Goa, Visakhapatnam (Andhra Pradesh) and Sikkim; where research centre at Pune and Aurangabad. Among these the baby plant is Nagpur plant which will the biggest formulation unit for Lupin in coming year.